tetano
Editor, Senior Moderator
Nat Med
. 2022 Apr 25.
doi: 10.1038/s41591-022-01832-0. Online ahead of print.
Effectiveness of a second BNT162b2 booster vaccine against hospitalization and death from COVID-19 in adults aged over 60 years
Ronen Arbel[SUP] 1 2 [/SUP], Ruslan Sergienko[SUP] 3 [/SUP], Michael Friger[SUP] 3 [/SUP], Alon Peretz[SUP] 4 [/SUP], Tanya Beckenstein[SUP] 4 [/SUP], Shlomit Yaron[SUP] 4 [/SUP], Doron Netzer[SUP] 4 [/SUP], Ariel Hammerman[SUP] 4 [/SUP]
Affiliations
Abstract
The rapid emergence of the B.1.1.529 (Omicron) variant of SARS-CoV-2 led to a global resurgence of coronavirus disease 2019 (COVID-19). Israeli authorities approved a fourth COVID-19 vaccine dose (second-booster) for individuals aged 60 years and over who had received a first booster dose four or more months earlier. Evidence regarding the effectiveness of a second-booster dose in reducing hospitalizations and mortality due to COVID-19 is warranted. This retrospective cohort study included all members of Clalit Health Services, aged 60 to 100 years, who were eligible for the second-booster on January 3, 2022. Hospitalizations and mortality due to COVID-19 among participants who received the second-booster were compared with participants who received one booster dose. Cox proportional-hazards regression models with time-dependent covariates were used to estimate the association between the second-booster and hospitalizations and death due to COVID-19 while adjusting for demographic factors and coexisting illnesses. A total of 563,465 participants met the eligibility criteria. Of those, 328,597 (58%) received a second-booster dose during the 40-day study period. Hospitalizations due to COVID-19 occurred in 270 of the second-booster recipients and in 550 participants who received one booster dose (adjusted hazard ratio 0.36; 95% confidence interval (CI): 0.31 to 0.43). Death due to COVID-19 occurred in 92 second-booster recipients and in 232 participants who received one booster dose (adjusted hazard ratio 0.22; 95% CI 0.17 to 0.28). This study demonstrates a substantial reduction in hospitalizations and deaths due to Covid-19 conferred by a second-booster in Israeli adults aged 60 years and over.
. 2022 Apr 25.
doi: 10.1038/s41591-022-01832-0. Online ahead of print.
Effectiveness of a second BNT162b2 booster vaccine against hospitalization and death from COVID-19 in adults aged over 60 years
Ronen Arbel[SUP] 1 2 [/SUP], Ruslan Sergienko[SUP] 3 [/SUP], Michael Friger[SUP] 3 [/SUP], Alon Peretz[SUP] 4 [/SUP], Tanya Beckenstein[SUP] 4 [/SUP], Shlomit Yaron[SUP] 4 [/SUP], Doron Netzer[SUP] 4 [/SUP], Ariel Hammerman[SUP] 4 [/SUP]
Affiliations
- PMID: 35468276
- DOI: 10.1038/s41591-022-01832-0
Abstract
The rapid emergence of the B.1.1.529 (Omicron) variant of SARS-CoV-2 led to a global resurgence of coronavirus disease 2019 (COVID-19). Israeli authorities approved a fourth COVID-19 vaccine dose (second-booster) for individuals aged 60 years and over who had received a first booster dose four or more months earlier. Evidence regarding the effectiveness of a second-booster dose in reducing hospitalizations and mortality due to COVID-19 is warranted. This retrospective cohort study included all members of Clalit Health Services, aged 60 to 100 years, who were eligible for the second-booster on January 3, 2022. Hospitalizations and mortality due to COVID-19 among participants who received the second-booster were compared with participants who received one booster dose. Cox proportional-hazards regression models with time-dependent covariates were used to estimate the association between the second-booster and hospitalizations and death due to COVID-19 while adjusting for demographic factors and coexisting illnesses. A total of 563,465 participants met the eligibility criteria. Of those, 328,597 (58%) received a second-booster dose during the 40-day study period. Hospitalizations due to COVID-19 occurred in 270 of the second-booster recipients and in 550 participants who received one booster dose (adjusted hazard ratio 0.36; 95% confidence interval (CI): 0.31 to 0.43). Death due to COVID-19 occurred in 92 second-booster recipients and in 232 participants who received one booster dose (adjusted hazard ratio 0.22; 95% CI 0.17 to 0.28). This study demonstrates a substantial reduction in hospitalizations and deaths due to Covid-19 conferred by a second-booster in Israeli adults aged 60 years and over.
